LOS ANGELES–(EMWNews)–Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global

biopharmaceutical company, today announced it will release its 2008

second quarter financial results before the market opens on Wednesday,

August 13, 2008. The company also said that senior management will host

an investor conference call the same day at 8:30 a.m. PT/11:30 a.m. ET

to review the company’s financial results.

The conference call will be available to interested parties through a

live audio webcast at www.abraxisbio.com

and www.earnings.com.

The call will also be archived and accessible at both sites for six

months.

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company

dedicated to the discovery, development and delivery of next-generation

therapeutics and core technologies that offer patients safer and more

effective treatments for cancer and other critical illnesses. The

company’s portfolio includes the world’s first and only protein-bound

chemotherapeutic compound (ABRAXANE), which is based on the company’s

proprietary tumor targeting technology known as the nab^TM

platform. The first FDA approved product to use this nab^TM

platform, ABRAXANE, was launched in 2005 for the treatment of metastatic

breast cancer. Abraxis trades on the NASDAQ Global Market under the

symbol ABII. For more information about the company and its products,

please visit www.abraxisbio.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions